Current Treatment Options for Spinal Muscular Atrophy

Overview of the Disease

A recent review published in the journal Drugs by a research team from the UK provides an in-depth analysis of treatment options for spinal muscular atrophy (SMA). This condition is characterized by the degeneration of motor neurons in the spinal cord, leading to progressive paralysis and, in severe cases, death. The severity of symptoms and outcomes can vary significantly depending on the type of SMA, which ranges from mild to severe.

For instance, Type 0 (the most severe) and Type I (the most common) typically present symptoms before six months of age, with affected children often not surviving past two years. Types II and III encompass a broader range of cases, whereas Type IV is the least severe, with symptoms manifesting in adulthood, allowing many patients to live to their full life expectancy with minimal motor disability.

Genetic Basis of Spinal Muscular Atrophy

SMA is primarily a genetic disorder caused by the deletion of the SMN1 gene, responsible for producing the survival motor neuron (SMN) protein, vital for the health of motor neurons. Although nearly all individuals possess a second similar gene, SMN2, which also codes for SMN, it does not produce sufficient levels of the protein to compensate for the loss caused by SMN1 deletion. Variability in disease presentation and life expectancy may be partially attributed to differences in SMN2 expression levels. Despite the challenges, the understanding of the genetic underpinnings of SMA has led to significant advancements in treatment options.

Current Research and Treatment Approaches

SMN-Targeted Therapies

The University of Edinburgh’s recent review categorizes SMA therapies into two main groups: SMN-targeted and SMN-independent therapies.

mRNA Therapy

One notable advancement in SMA treatment is the biologic nusinersen, marketed as Spinraza. This therapeutic agent is a short mRNA sequence that binds to SMN2 mRNA, enhancing the production of SMN protein. Clinical trials have demonstrated promising results for Spinraza.

Gene Therapy

Gene therapy represents a direct approach to address SMA by delivering a functional copy of the SMN1 gene. This technique aims to correct the underlying genetic defect, enabling normal protein expression. While gene therapy holds great potential, it also raises concerns regarding patient safety and the long-term efficacy of introducing new DNA into the body.

Small Molecule Drugs

More traditional pharmaceutical approaches have also been explored to increase SMN protein levels. Initial efforts focused on enhancing SMN2 mRNA production by inhibiting enzymes that suppress this process. However, the medical community has concluded that these methods may lack sufficient clinical benefit, although they provide valuable insights for future research.

SMN-Independent and Combination Therapies

Several therapies that do not specifically target SMN have undergone clinical trials and are in development. These treatments generally aim to stimulate neuroprotective factors or enhance muscle strength. While they are simpler and have progressed more easily through trials, their optimal effectiveness is likely to be achieved when combined with SMN-targeted therapies. Monotherapy is unlikely to halt or reverse disease progression; thus, addressing both the root cause and secondary factors offers the greatest promise.

Challenges in Treatment

Significant challenges persist in the treatment of SMA, particularly due to the variability in clinical features among patients, which may affect individual responses to treatments. Additionally, timely diagnosis is critical, as delays can limit treatment options after the optimal intervention window has passed.

Conclusion

Despite the complexities associated with SMA, the advancements made in recent years are noteworthy and indicate a positive trajectory towards more effective treatments for this previously considered incurable condition.

Written by Adriano Vissa, PhD

Reference: Shorrock HK, Gillingwater TH, and Groen EJN. Overview of Current Drugs and Molecules in Development for Spinal Muscular Atrophy Therapy. Drugs. (2018) 78:293-305.